DEF: Avenue Therapeutics Sets 2025 Annual Meeting, Elects Directors

Avenue Therapeutics, Inc. announced its virtual Annual Meeting of Stockholders for December 30, 2025, to elect directors and ratify KPMG LLP as its independent auditor.

Summary

• The Annual Meeting of Stockholders will be held virtually on Tuesday, December 30, 2025, at 10:00 a.m. Eastern Time.
• Stockholders will vote on the election of six directors for a one-year term.
• Stockholders will also vote to ratify the appointment of KPMG LLP as the independent registered public accounting firm for the year ending December 31, 2025.
• The record date for voting is November 25, 2025, with 3,183,426 shares of common stock and 250,000 shares of Class A Preferred Stock outstanding.
• Fortress Biotech, Inc. holds 100% of the Class A Preferred Stock, which carries super-voting rights (14.0 votes per share on the record date), ensuring Fortress maintains voting control.
• The company completed a 1-for-75 reverse stock split on April 26, 2024.

Sentiment

Score: 4

Explanation: The filing is primarily a procedural proxy statement for an annual meeting, focusing on director elections and auditor ratification. While it highlights good corporate governance practices like independent directors and a clawback policy, it also reveals continued net losses and the termination of a significant license agreement (AJ201), which could be seen as a setback. Executive compensation reflects these challenges, with no bonus for the CEO in 2024. The company's reliance on Fortress Biotech for funding and its 'controlled company' status are also notable.

Positives

• The Board of Directors is comprised of a majority of independent directors, and the Compensation Committee is separately constituted and composed of independent directors, exceeding minimum requirements for controlled companies.
• The company has adopted a Clawback Policy for erroneously awarded incentive-based compensation, effective October 2, 2023, enhancing executive accountability.
• An Insider Trading Policy is in place, prohibiting speculative trading, hedging, and short sales by officers, directors, and employees, promoting compliance and reducing conflicts of interest.

Negatives

• The Compensation Committee determined not to grant any bonus to CEO Alexandra MacLean for 2024 due to overall economic and business conditions of the company.
• Interim CFO and COO David Jin received no salary and no discretionary bonus in 2024.
• The company reported net losses of $11.7 million in 2024, $10.4 million in 2023, and $3.6 million in 2022.
• The license agreement with AnnJi Pharmaceutical for AJ201 was terminated on April 24, 2025, with Avenue transferring all rights back to AnnJi, indicating a potential setback in its pipeline.

Risks

• The company's primary focus on research and development of therapies for neurologic diseases means net income (loss) has not historically been a performance measure for its executive compensation program, and there is little correlation between Compensation Actually Paid and net income (loss).
• Significant turnover in PEO and non-PEO NEO roles occurred between 2022-2024, which could impact leadership stability and strategic execution.
• Fortress Biotech, Inc. beneficially owns capital stock representing more than 50% of the voting power, qualifying Avenue as a controlled company and giving Fortress voting control, which may limit the influence of other shareholders.
• Fortress and its affiliates are contractually exempt from fiduciary duties to the Company relating to corporate opportunities, potentially leading to missed opportunities for Avenue.
• The termination of the AnnJi License Agreement means Avenue is prohibited from developing, commercializing, manufacturing, or selling any product competing with AJ201 in the US, Canada, the European Union, Great Britain, or Israel for 48 months.

Future Outlook

The Board may engage a compensation consultant to conduct a review of its executive compensation programs in 2025. The company will not develop, commercialize, manufacture, or sell any product competing with AJ201 in the US, Canada, the European Union, Great Britain, or Israel for 48 months following the termination of the AnnJi License Agreement.

Management Comments

• "We look forward to virtually seeing you at the Annual Meeting." Alexandra MacLean, M.D., Chief Executive Officer.
• "We are committed to engagement with our stockholders." Company statement regarding submitting questions at the Annual Meeting.

Industry Context

The company operates in the biopharmaceutical industry, focusing on research and development of therapies for neurologic diseases. Its status as a 'controlled company' due to Fortress Biotech's majority voting power is a notable structural aspect, which is common in certain biotech funding models. The termination of the AJ201 license agreement with AnnJi Pharmaceutical indicates a shift in its pipeline focus or a re-evaluation of its development strategy for spinal and bulbar muscular atrophy (SBMA).

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• Fortress Biotech, Inc. (parent company and 5% beneficial owner) is involved in a Founders Agreement, Management Services Agreement, and holds all Class A Preferred Stock with super-voting rights, ensuring voting control.
• Fortress received 43,772 common shares in 2024 and 699 common shares in 2023 as a Financing Equity Fee.
• The company incurred $250,000 in expenses related to the Management Services Agreement with Fortress in 2024 and $500,000 in 2023.
• In November 2024, Fortress Biotech, Inc. converted 50% of a $0.5 million debt owed by the company into 122,850 common shares and forgave the remaining 50%.
• The company acquired Baergic Bio, Inc. from Fortress in November 2022, with no cash or securities paid to Fortress. The Avenue-Baergic Founders Agreement and MSA were subsequently terminated on November 5, 2025, due to the sale of Baergic.
• Dr. Lindsay A. Rosenwald (director) participated in the September 2023 Private Placement, purchasing shares alongside Fortress.
• Dr. Jay Kranzler (Chairman) received $50,000 in consulting fees from Baergic in 2024, which was terminated in October 2025.

Stakeholder Impact

• Shareholders will vote on director elections and auditor ratification. Fortress Biotech, as the holder of Class A Preferred Stock, maintains voting control, which could limit the influence of common stockholders on certain matters. The 1-for-75 reverse stock split impacts the number of shares held.
• Employees and Executives: Executive compensation for 2024 saw no bonus for the CEO and no salary/bonus for the Interim CFO/COO, reflecting challenging economic and business conditions. The Clawback Policy increases accountability for incentive-based compensation.
• Creditors: Fortress Biotech converted $0.25 million of debt into equity and forgave another $0.25 million, reducing the company's liabilities.
• Partners (AnnJi Pharmaceutical): The termination of the AJ201 license agreement means Avenue will no longer develop this product, but is eligible for future milestone and royalty payments from AnnJi.

Next Steps

• Hold the Annual Meeting of Stockholders virtually on December 30, 2025, to elect directors and ratify the independent registered public accounting firm.
• The Board may engage a compensation consultant to review executive compensation programs in 2025.
• Stockholders can submit proposals for the 2026 Annual Meeting under Rule 14a-8 by August 7, 2026, or provide advance notice for other proposals between November 10, 2026, and October 1, 2026.
• AnnJi Pharmaceutical will make payments totaling up to $5 million upon certain development and regulatory milestones for AJ201, up to $17 million upon commercial sales milestones, and a 1.75% royalty on net sales, following the termination of the license agreement.

Key Dates

Recommendation

The filing is a routine proxy statement for an annual meeting, not a financial results announcement. It highlights stable corporate governance with independent oversight and a commitment to ethical practices. However, the company continues to report net losses, and the termination of the AnnJi license agreement for AJ201 represents a setback in its pipeline, albeit with potential future milestone and royalty payments. The 'controlled company' status and ongoing related-party transactions with Fortress Biotech are structural elements to consider. Given the lack of new positive operational or financial catalysts in this filing, a 'hold' recommendation is appropriate, awaiting further clarity on the company's strategic direction and financial performance.

Keywords

Avenue Therapeutics, ATXI, Proxy Statement, Annual Meeting, Corporate Governance, Director Election, Auditor Ratification, SEC Filing, Biopharmaceutical, Fortress Biotech, Executive Compensation, Related Party Transactions, AJ201, SBMA